

ALKERMES INC
Form DEFA14A
May 12, 2011

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES
EXCHANGE ACT OF 1934 (Amendment No.)**

Filed by the Registrant ☐

Filed by a Party other than the Registrant ☐

Check the appropriate box:

- ☐ Preliminary Proxy Statement
- ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- ☐ Definitive Proxy Statement
- ☐ Definitive Additional Materials
- ☐ Soliciting Material Pursuant to § Rule 14a-12

ALKERMES, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- ☐ No fee required.
- ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

- | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| (1) Title of each class of securities to which transaction applies: | NOT APPLICABLE |
| (2) Aggregate number of securities to which transaction applies: | NOT APPLICABLE |
| (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | NOT APPLICABLE |
| (4) Proposed maximum aggregate value of transaction: | NOT APPLICABLE |
| (5) Total fee paid: | NOT APPLICABLE |
| <input type="checkbox"/> Fee paid previously with preliminary materials: | NOT APPLICABLE |

Edgar Filing: ALKERMES INC - Form DEFA14A

- o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:	NOT APPLICABLE
(2) Form, Schedule or Registration Statement No.:	NOT APPLICABLE
(3) Filing Party:	NOT APPLICABLE
(4) Date Filed:	NOT APPLICABLE

This filing relates to a planned merger (Merger) between Alkermes, Inc. and the global drug delivery technologies business of Elan (known as EDT) (such combination, the Business Combination) pursuant to a Business Combination Agreement and Plan of Merger (the Business Combination Agreement) by and among Elan Corporation, plc (Elan), a public limited company incorporated in Ireland, Antler Science Two Limited, a private limited company incorporated in Ireland, Elan Science Four Limited, a private limited company incorporated in Ireland, EDT Pharma Holdings Limited, a private limited company incorporated in Ireland, EDT US Holdco, Inc., a Delaware corporation, Antler Acquisition Corp., a Pennsylvania corporation and direct wholly owned subsidiary of U.S. Holdco, and Alkermes, Inc., a Pennsylvania corporation. The businesses will be combined under New Alkermes, a new holding company incorporated in Ireland that will be re-registered as a public limited company, and renamed Alkermes, plc, at or prior to the completion of the Business Combination. The Business Combination Agreement is on file with the Securities and Exchange Commission as an exhibit to the Current Report on Form 8-K filed by Alkermes, Inc. on May 9, 2011. Alkermes has prepared an investor presentation which was made available beginning on May 12, 2011 regarding the matters described above. A copy of the investor presentation is attached hereto and is incorporated herein by reference.

Forward Looking Statements

Information set forth herein contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties. Alkermes cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such forward-looking statements include, but are not limited to, statements about the benefits of the business combination transaction involving EDT and Alkermes, including future financial and operating results, the combined company's plans, objectives, expectations (financial or otherwise) and intentions and other statements that are not historical facts.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the failure of Alkermes stockholders to approve the transaction; the outcome of pending or potential litigation or governmental investigations; the risk that the businesses will not be integrated successfully or such integration may be more difficult, time-consuming or costly than expected; uncertainty of the expected financial performance of Alkermes plc following completion of the proposed transaction; Alkermes plc's ability to achieve the cost savings and synergies contemplated by the proposed transaction within the expected time frame; disruption from the proposed transaction making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; and the calculations of, and factors that may impact the calculations of, the acquisition price in connection with the proposed merger and the allocation of such acquisition price to the net assets acquired in accordance with applicable accounting rules and methodologies. Additional information and other factors are contained in Alkermes filings with the Securities and Exchange Commission, including Alkermes Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other SEC filings, which are available at the SEC's web site <http://www.sec.gov>. Alkermes disclaims any obligation to update and revise statements contained in these materials based on new information or otherwise.

Important Additional Information and Where to Find It

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

In connection with the proposed merger, Alkermes plc will file with the SEC a registration statement on Form S-4 that will include a preliminary prospectus regarding the proposed merger and Alkermes will file with the SEC a proxy statement in respect of the proposed merger. After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to Alkermes stockholders in connection with the proposed merger. INVESTORS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE MERGER FILED WITH THE SEC WHEN THEY BECOME

AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ALKERMES, EDT AND THE PROPOSED MERGER. You may obtain a copy of the registration statement and the proxy statement/prospectus (when available) and other related documents filed by Alkermes and Elan with the SEC regarding the proposed merger as well as other filings containing information about Alkermes, Elan and the merger, free of charge, through the web site maintained by the SEC at www.sec.gov, by directing a request to Alkermes Investor Relations department at Alkermes, Inc., 852 Winter Street, Waltham, Massachusetts 02451, Attn: Investor Relations or to Alkermes Investor Relations department at (781) 609-6000 or by email to financial@alkermes.com. Copies of the proxy statement/prospectus and the filings with the SEC that will be incorporated by reference in the proxy statement/prospectus can also be obtained, when available, without charge, from Alkermes website at www.Alkermes.com under the heading Investor Relations and then under the heading SEC Filings .

Participants in Solicitation

This communication is not a solicitation of a proxy from any Alkermes shareholder. Alkermes and its directors, executive officers and certain other members of management and employees may, however, be deemed to be participants in the solicitation of proxies in respect of the proposed merger. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of proxies in respect of the proposed merger will be set forth in the registration statement and the proxy statement/prospectus when it is filed with the SEC. You can find information about Alkermes directors and executive officers in its definitive proxy statements filed with the SEC on July 29, 2010. You can obtain free copies of these documents as described above.

Alkermes plc: Products, Profitability and Growth May 2011

Certain statements in this presentation may constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the operational and financial benefits of the business combination. Forward-looking information is not a guarantee of future performance. Actual results may differ materially from those contained in the forward-looking information due to a number of factors including: (i) the ability to obtain required regulatory approval and stockholder consent, and to satisfy other conditions, required to consummate the merger; (ii) whether anticipated financial and operational benefits from the proposed merger will be realized within the expected time frame or at all; (iii) whether the businesses will be integrated successfully or whether such integration may be more difficult, time consuming or costly than expected; and (iv) the cost and outcome of potential litigation relating to the transaction. For additional factors, which could cause actual results to differ from expectations, reference is made to the reports filed by the company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.

Important Additional Information and Where to Find It This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to or qualification under the securities laws of any such jurisdiction. In connection with the proposed merger, Alkermes plc will file with the SEC a registration statement on Form S-4 that will include a preliminary prospectus regarding the proposed merger and Alkermes will file with the SEC a proxy statement in respect of the proposed merger. After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to Alkermes **INVESTORS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE MERGER FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ALKERMES, EDT AND THE PROPOSED MERGER.** You may obtain a copy of the registration statement and the proxy statement/prospectus (when available) and other related documents filed by Alkermes and Elan with the SEC regarding the proposed merger as well as other filings containing information about Alkermes, Elan and the merger, free of charge, through the web site maintained by the SEC at www.sec.gov, by directing a request to Alkermes 852 Winter Street, Waltham, Massachusetts 02451, Attn: at (781) 609-6000 or by email to financial@alkermes.com. Copies of the proxy statement/prospectus and the filings with the SEC that will be incorporated by reference in the proxy statement/prospectus can also be obtained, when available, without charge, from Alkermes www.Alkermes.com website at under the heading **Investor SEC Filings** . **Participants in Solicitation** This communication is not a solicitation of a proxy from any Alkermes shareholder. Alkermes and its directors, executive officers and certain other members of management and employees may, however, be deemed to be participants in the solicitation of proxies in respect of the proposed merger. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of proxies in respect of the proposed merger will be set forth in the registration statement and the proxy statement/prospectus when it is filed with the SEC. You can find information about Alkermes directors and executive officers in its obtain free copies of these documents as described above.

Alkermes and EDT: A Transformational Transaction Financially Operationally o Immediate profitability
on a o Global biopharmaceutical cash earnings basis and company with proven track expanding Adjusted
EBITDA record of innovation margins o Leader in CNS product o Accretive transaction development o
Growing revenues in excess o Operating at a new scale of \$450 million annually ~1,200 employees
Driven by five major R&D expertise based on commercial products with proprietary technologies long
patent lives World-class manufacturing o Incorporated in Ireland in U.S. and Ireland

Five Major Products Drive Long-Term Growth AMPYRA® (18% manufacturing and royalty rate) o Treatment to improve walking in patients with multiple sclerosis (MS) o Launched in U.S. in 2010, MAA filed in Europe o Patent life into 2026 VIVITROL® (Proprietary product) o Once-monthly injectable medication for alcohol and opioid dependence o Ramping launch in opioid indication o Patent life into 2029 BYDUREON (8% royalty rate) o First once-weekly GLP-1 for type 2 diabetes o CHMP recommendation for approval in Europe o Patent life into 2025 RISPERDAL® CONSTA® (10% manufacturing and royalty rate, ~7.5% net) o Leading long-acting injectable antipsychotic for schizophrenia/bipolar I disorder o Approved in >90 countries, \$1.5 billion in end-market sales o Patent life into 2020 in U.S. / 2021 in Europe INVEGA® SUSTENNA® (Tiered royalty rates on par with RISPERDAL CONSTA net economics) o Long-acting injectable antipsychotic for schizophrenia o Approved in U.S. and Europe, recent UK launch o Patent life into 2019 COPYRIGHT © 2011 ALKERMES, INC.

® AMPYRA® o Treatment to improve walking in patients with multiple sclerosis (MS) o Expands Alkermes therapeutic scope into MS o Launched in U.S. in 2010, MAA filed in Europe o Marketed by Acorda in U.S., partnered with Biogen Idec in Europe o Patent life into 2026 o 18% manufacturing and royalty rate

® VIVITROL® o Once-monthly injectable medication for alcohol and opioid dependence o Currently launching opioid indication o Patent life into 2029 o Proprietary product, currently marketed by Alkermes in U.S. 1. LTM (last twelve months) as of 12/31/2010 COPYRIGHT © 2011 ALKERMES, INC.

® BYDUREON o First once-weekly GLP-1 for type 2 diabetes o Long-acting version of Amylin s
BYETTA® (\$538 million LTM¹ sales) o CHMP recommendation for approval in Europe on 4/15/2011,
anticipated launch 2H 2011 o Planned U.S. resubmission 2H 2011 o Patent life into 2025 o Marketed by
Eli Lilly and Amylin o 8% royalty rate 1. LTM as of 3/31/2011 COPYRIGHT © 2011 ALKERMES, INC.

® RISPERDAL® CONSTA o Leading long-acting injectable antipsychotic for schizophrenia/bipolar I disorder o Approved in over 90 countries, \$1.5 billion in end-market sales o Johnson & rd largest pharmaceutical brand by product revenues in 2010 o Patent life into 2020 in U.S., 2021 in Europe o 10% manufacturing and royalty rate, ~7.5% net o ~4% atypical antipsychotic market share in U.S. 1. LTM as of 12/31/2010 COPYRIGHT © 2011 ALKERMES, INC.

® INVEGA® SUSTENNA® o Long-acting injectable antipsychotic for schizophrenia o First monthly depot schizophrenia drug o First commercialized NanoCrystal® depot product o Approved in U.S. and Europe, recent UK launch o Marketed by Johnson & Johnson o Patent life into 2019 o Tiered royalty rates on par with RISPERDAL® CONSTA® net economics COPYRIGHT © 2011 ALKERMES, INC.

® Combined Pipeline: CNS Focus Reward Schizophrenia Depression Disorders Pain OIC MS ALKS 9070 ALKS 33/BUP ALKS 33 Meloxicam IV ALKS 37 AMPYRA® (binge eating) RISPERDAL® ZX002 CONSTA® ALKS 33 (alcohol ALKS 36 INVEGA® dependence) SUSTENNA® ALKS 33/BUP (cocaine addiction) VIVITROL® COPYRIGHT © 2011 ALKERMES, INC.

® Strong Strategic Fit at the Right Time o EDT positioned for growth; AMPYRA® and INVEGA® SUSTENNA® at beginning of their growth trajectories o Complementary world-class drug formulation and manufacturing expertise o CNS focused product portfolios - Royalties from long-acting atypical antipsychotics now under one roof o Capability to invest prudently in the strongest pipeline assets

® EDT: Established Model for Profitability o 40-year history with >35 approved drugs o Commercial portfolio of 22 marketed drugs o NanoCrystal® and Oral Controlled Release technologies o Track record of innovation: AMPYRA®, AVINZA®, NAPRELAN® and VERELAN® o Diversified revenue streams Royalties on commercialized products - R&D revenues from partnered candidates Manufacturing revenues COPYRIGHT © 2011 ALKERMES, INC.

® Deep Product Portfolio with Diversified Revenue Streams Products Mfg Rev Royalties (\$MM) 300
Avinza® 274 Luvox® CR Diltiazem® Naprelan® Rapamune® 200 Ritalin® LA / Focalin® XR
Verelan® Zanaflex® Capsules 104 Emend® 100 Megace® ES Skelaxin® Tricor® 145
Recent Launches Mfg Rev Royalties 0 Ampyra® CY 10 Invega® Sustenna® Revenue Adjusted
EBITDA COPYRIGHT © 2011 ALKERMES, INC.

® Key Transaction Terms Purchase Price Cash: \$500 million Equity: 31.9 million shares (~25% of pro forma company) Combination of cash on balance sheet and prepayable new term loan Funding New debt of up to \$450 million with secured financing from Morgan Stanley and HSBC Pro forma company immediately profitable on a cash earnings basis Financial Impact Immediately accretive to cash earnings Pro forma debt / Adjusted EBITDA of 4.6x to be reduced through future growth in EBITDA and debt paydown Synergies ~\$20 million synergies to be Closing Conditions Alkermes shareholder approval Customary closing conditions and HSR clearance Shareholder Elan has entered into a shareholder agreement with respect to its Agreement holdings in the pro forma company Transaction Close Expected Q3 CY 11

® Alkermes plc: Financial Strength o Trailing 12 months as of March 31, 2011 Pro forma revenues ~\$450 million Pro forma Adjusted EBITDA ~\$80 million o Pro forma revenues Double-digit growth rates o Pro forma Adjusted EBITDA margins Expected to be in range of 15-20% in Expand to 30-35% in FY 13 and o \$20 million in annual synergies in U.S. operations to be fully realized by COPYRIGHT © 2011 ALKERMES, INC.

® Meaningful Increase in Revenues & Profitability Revenue Adj. EBITDA

® Alkermes plc: Diversified Revenue Base (based on CY 10)

® Alkermes and EDT: A Transformational Transaction Financially Operationally o Immediate profitability on a o Global biopharmaceutical cash earnings basis and company with proven track expanding Adjusted EBITDA record of innovation margins o Leader in CNS product o Accretive transaction development o Growing revenues in excess o Operating at a new scale of \$450 million annually ~1,200 employees Driven by five major R&D expertise based on commercial products with proprietary technologies long patent lives World-class manufacturing o Incorporated in Ireland in U.S. and Ireland Accelerates profitability and provides springboard for growth COPYRIGHT © 2011 ALKERMES, INC.

www.alkermes.com